Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
Starting soon · Phase 4 · Has a placebo group
Conditions studied: Chronic Kidney Diseases
In brief
The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.
Key facts
- Study ID
- NCT07074418
- Run by
- Centre Hospitalier Universitaire de Nice
- People needed
- 34
- Starts
- 2026-09-01
- Expected to finish
- 2028-05-01
- Last updated by the study team
- 2026-07-27
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- type 2 diabetics,
- age between 18 and 80 years,
- RAS blockade at maximal tolerated dosage for 1 month,
- eGFR (CKD-EPI) between 10 and 20 ml/min/1.73m2,
- UACR > 300mg/g creatinine and UPCR > 500mg/g creatinine,
- office systolic blood pressure > 110 mmHg,
- stable dosage of antihypertensive drugs and diuretics for 1 month.
You may not qualify if…
- any medical condition that, in the opinion of the investigator makes the participant not suitable for inclusion,
- history of ketoacidosis in the past while on empagliflozin or any other SGLT2i class drugs,
- participation in another clinical study with an investigational medicinal product (IMP) administered during the month before screening,
- known hypersensitivity or intolerance to empagliflozin or any of the excipients of the product,
- judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements,
- no social insurance,
- unwilling to give informed consent, vulnerable persons (minors, adults under guardianship or trusteeship, pregnant women, persons deprived of their liberty, persons unable to speak French).
Where it is running
- CHU Nice - Hôpital Pasteur 2 — Nice, Alpes-Maritimes, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.